Comparisons of Treatment Patterns for Type 2 Diabetes Mellitus (T2DMm) in Japan and in the United States

Abstract

A903fied by age (65-74, 75-84, 85+). Results: In the first year after cohort enrollment, the average monthly anticholinergic burden measured by the ARS, ACB and DBI-Ach was 0.26, 0.60 and 0.04, respectively. Compared to the ARS and DBI-Ach, the ACB showed a strong dose-response relationship with risk for each of the adverse outcomes, particularly in people aged 65-84. For example, in people aged 65-74, ACB scores = 1-4+, emergency room visits: adjusted odds ratio (aOR) ranged from 1.41-2.25, all-cause hospitalization: aOR ranged from 1.32-1.92, fracture-specific hospitalization: aOR ranged from 1.10-1.71, incident dementia: aOR ranged from 3.13-10.01). ConClusions: The ACB scale is more selective than the ARS and the DBI-Ach in identifying medications likely to cause adverse outcomes, including emergency room visits, all-cause hospitalization, fracture-specific hospitalization and incident dementia in the elderly.

Empagliflozin as add‐on to linagliptin in a fixed‐dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52‐week, randomized, placebo‐controlled trial

“…Dipeptidyl peptidase‐4 (DPP‐4) inhibitors stimulate glucose‐dependent insulin secretion via increased levels of active glucagon‐like peptide‐1 (GLP‐1), resulting in lower glycated haemoglobin (HbA1c) and fasting plasma glucose (FPG), with low risk of hypoglycaemia . DPP‐4 inhibitors improve glycaemic control in Asian patients, possibly because Asian patients have reduced insulin secretion capacity, and are the most commonly prescribed OAD in Japan . Linagliptin is a potent and selective DPP‐4 inhibitor, with demonstrated efficacy and safety, including in Japanese patients .…”